[go: up one dir, main page]

CL2016002372A1 - Cenicriviroc para el tratamiento de la fibrosis. - Google Patents

Cenicriviroc para el tratamiento de la fibrosis.

Info

Publication number
CL2016002372A1
CL2016002372A1 CL2016002372A CL2016002372A CL2016002372A1 CL 2016002372 A1 CL2016002372 A1 CL 2016002372A1 CL 2016002372 A CL2016002372 A CL 2016002372A CL 2016002372 A CL2016002372 A CL 2016002372A CL 2016002372 A1 CL2016002372 A1 CL 2016002372A1
Authority
CL
Chile
Prior art keywords
cenicriviroc
fibrosis
treatment
affection
administer
Prior art date
Application number
CL2016002372A
Other languages
English (en)
Inventor
Eric Lefebre
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of CL2016002372A1 publication Critical patent/CL2016002372A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)

Abstract

<p>UN METODO PARA TRATAR LA FIBROSIS O UNA AFECCION O ENFERMEDAD FIBROTICA, QUE COMPRENDE ADMINISTRAR DE FORMA CONJUNTA CENICRIVIROC Y UN AGENTE ACTIVO ADICIONAL.</p>
CL2016002372A 2014-03-21 2016-09-21 Cenicriviroc para el tratamiento de la fibrosis. CL2016002372A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968829P 2014-03-21 2014-03-21
US201462024713P 2014-07-15 2014-07-15
US201562114304P 2015-02-10 2015-02-10

Publications (1)

Publication Number Publication Date
CL2016002372A1 true CL2016002372A1 (es) 2017-02-10

Family

ID=54145485

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002372A CL2016002372A1 (es) 2014-03-21 2016-09-21 Cenicriviroc para el tratamiento de la fibrosis.

Country Status (16)

Country Link
US (3) US20170239262A1 (es)
EP (2) EP3119401A4 (es)
JP (1) JP6556825B2 (es)
KR (1) KR20160132489A (es)
CN (1) CN106488769A (es)
AU (2) AU2015230986A1 (es)
BR (1) BR112016021682A2 (es)
CA (1) CA2941411A1 (es)
CL (1) CL2016002372A1 (es)
HK (1) HK1232147A1 (es)
IL (1) IL247515A0 (es)
MA (1) MA39748A (es)
MX (1) MX2016012262A (es)
RU (2) RU2724339C2 (es)
SG (2) SG10201808104RA (es)
WO (1) WO2015143367A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2376855T3 (es) 2001-08-08 2012-03-20 Tobira Therapeutics, Inc. Compuesto bicíclico, su preparación y su uso
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
MX383706B (es) * 2013-05-15 2025-03-14 Tobira Therapeutics Inc Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
EP3191100A4 (en) * 2014-09-12 2018-05-30 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
EP3207123A1 (en) 2014-10-17 2017-08-23 Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CN107207538A (zh) 2014-12-23 2017-09-26 妥必徕疗治公司 制备cenicriviroc及相关类似物的方法
CA2998509A1 (en) * 2015-09-16 2017-03-23 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2017103001A2 (en) * 2015-12-16 2017-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections
FR3050112B1 (fr) 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
US11066650B2 (en) 2016-05-05 2021-07-20 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
SG11201811140UA (en) 2016-06-21 2019-01-30 Tobira Therapeutics Inc Purified cenicriviroc and purified intermediates for making cenicriviroc
CN106248947A (zh) * 2016-07-21 2016-12-21 中国人民解放军军事医学科学院基础医学研究所 一种哺乳动物高原脑水肿生物标志物及其应用
TW201823235A (zh) 2016-08-31 2018-07-01 美商托彼拉治療公司 西克里維羅（ｃｅｎｉｃｒｉｖｉｒｏｃ）甲磺酸鹽之固體型式和製造西克里維羅甲磺酸鹽之固體型式的方法
EP4553082A3 (en) 2016-11-04 2025-08-20 Children's Hospital Medical Center Liver organoid compositions and methods of making and using same
KR102807995B1 (ko) 2016-12-05 2025-05-16 칠드런즈 호스피탈 메디칼 센터 결장 유사장기 및 이를 제조 및 사용하는 방법
CN110418641A (zh) * 2017-02-24 2019-11-05 基恩菲特公司 用于组合疗法的药物组合物
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
CN111565798B (zh) 2017-10-10 2025-06-24 儿童医院医学中心 食道组织和/或类器官组合物及其制备方法
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
JP7263659B2 (ja) * 2018-02-02 2023-04-25 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド カルボン酸基を含む窒素含有ベンゾ複素環化合物、その調製方法及び使用
GB201804922D0 (en) 2018-03-27 2018-05-09 Ucl Business Plc Traatment
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
KR20210057781A (ko) 2018-09-12 2021-05-21 칠드런즈 호스피탈 메디칼 센터 조혈 줄기세포 및 이의 파생체의 생산을 위한 오르가노이드 조성물
WO2021133811A1 (en) * 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
JP2023538533A (ja) * 2020-08-07 2023-09-08 ブリストル－マイヤーズ スクイブ カンパニー 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１
WO2023133607A1 (en) * 2022-01-14 2023-07-20 Dimerix Bioscience Pty Ltd Compositions comprising a chemokine receptor pathway inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE346042T1 (de) * 1999-12-08 2006-12-15 Teijin Ltd Zyklische aminverbindungen als ccr5-rezeptor antagonisten
ES2376855T3 (es) * 2001-08-08 2012-03-20 Tobira Therapeutics, Inc. Compuesto bicíclico, su preparación y su uso
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
US20080031942A1 (en) 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
MX2007015085A (es) * 2005-05-31 2008-01-17 Novartis Ag Tratamiento de enfermedades del higado en donde el hierro juega un papel importante en patogenesis.
US7683176B2 (en) * 2006-07-14 2010-03-23 Chemocentryx, Inc. Triazolyl pyridyl benzenesulfonamides
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
JP2010505878A (ja) * 2006-10-05 2010-02-25 セントコア・オーソ・バイオテツク・インコーポレーテツド 線維症の処置のためのｃｃｒ２アンタゴニスト
RU2337365C1 (ru) * 2006-12-12 2008-10-27 Государственное образовательное учреждение высшего профессионального образования Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО НГМУ Росздрава) Способ дифференциальной диагностики алкогольного и неалкогольного стеатогепатита
RU2435593C2 (ru) * 2009-07-21 2011-12-10 Лев Давидович Раснецов Фармацевтическая композиция для лечения сахарного диабета 2 типа и лекарственное средство на его основе
MX383706B (es) * 2013-05-15 2025-03-14 Tobira Therapeutics Inc Composiciones de cenicriviroc y métodos para elaborarlas y usarlas.

Also Published As

Publication number Publication date
RU2020119611A (ru) 2020-06-29
JP6556825B2 (ja) 2019-08-07
RU2724339C2 (ru) 2020-06-23
IL247515A0 (en) 2016-11-30
KR20160132489A (ko) 2016-11-18
AU2015230986A1 (en) 2016-10-13
US20190099429A1 (en) 2019-04-04
BR112016021682A2 (pt) 2018-06-26
EP3119401A4 (en) 2017-12-13
CA2941411A1 (en) 2015-09-24
EP3922246A1 (en) 2021-12-15
US20200368247A1 (en) 2020-11-26
AU2020203867A1 (en) 2020-07-02
MA39748A (fr) 2021-04-21
SG10201808104RA (en) 2018-10-30
WO2015143367A2 (en) 2015-09-24
CN106488769A (zh) 2017-03-08
US20170239262A1 (en) 2017-08-24
RU2016141281A (ru) 2018-04-23
RU2016141281A3 (es) 2018-10-26
HK1232147A1 (zh) 2018-01-05
JP2017509704A (ja) 2017-04-06
SG11201607859SA (en) 2016-10-28
EP3119401A2 (en) 2017-01-25
MX2016012262A (es) 2017-01-06

Similar Documents

Publication Publication Date Title
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
CL2015002535A1 (es) Compuestos aromáticos sustituidos y método relacionado para el tratamiento de la fibrosis
IL249061B (en) Combination, composition, and method of administering the combination or composition to animals
CL2016002971A1 (es) Combinación.
EP3288520A4 (en) Use of active agents during chemical treatments
EA201790398A1 (ru) Способы лечения заболевания печени
MX378273B (es) Compuestos activos hacia bromodominios.
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
GT201700280A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
PT3678349T (pt) Configuração de verificação de estado com utilização de mensagens de troca de chaves de internet
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
MX2017004629A (es) Compuesto heterociclico.
BR112017019025A2 (pt) aplicadores de implante e métodos para administrar implantes.
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX392383B (es) Metodos para tratar afecciones oculares.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2016014307A (es) Administración asistida de agentes de tratamiento de plantas.
LT3373996T (lt) Aktyvuotų kamieninių ląstelių generavimo, naudojimo ir tiekimo būdas
LT3229790T (lt) Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme
ITUB20152180A1 (it) Metodo migliorato per conciare una pelle animale.
EP3220920C0 (en) COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG-RESISTANT MICROORGANISMS
BR112017013579A2 (pt) método para uso de uma cepa de bacillus subtilis ou bacillus pumilus para tratar ou impedir a doença do abacaxi.
ES2811674R1 (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
MX2023009895A (es) Compuestos y composiciones para tratar la fibrosis.